Scientists at Helmholtz Zentrum München have developed a new package called Scanpy that they hope will support major analytical efforts, such as the Human Cell Atlas.
The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.
Paris-based Scipio will use the seed funding to further develop and commercialize its first prototype kit for single-cell transcriptomics.
Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.
In Science this week: ancient Neanderthal and human genomes, and more.
The UK-based company plans to use the funds to develop an automated, benchtop device for the creation of high-value, genome-edited cell lines.
The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.
The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.